104 related articles for article (PubMed ID: 20195292)
1. Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia.
Kuzman MR; Medved V; Bozina N; Grubišin J; Jovanovic N; Sertic J
Pharmacogenomics J; 2011 Feb; 11(1):35-44. PubMed ID: 20195292
[TBL] [Abstract][Full Text] [Related]
2. The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients.
Kuzman MR; Medved V; Bozina N; Hotujac L; Sain I; Bilusic H
Psychiatry Res; 2008 Sep; 160(3):308-15. PubMed ID: 18718676
[TBL] [Abstract][Full Text] [Related]
3. MDR1 gene polymorphisms and response to acute risperidone treatment.
Kastelic M; Koprivsek J; Plesnicar BK; Serretti A; Mandelli L; Locatelli I; Grabnar I; Dolzan V
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):387-92. PubMed ID: 20060871
[TBL] [Abstract][Full Text] [Related]
4. HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.
Ma X; Maimaitirexiati T; Zhang R; Gui X; Zhang W; Xu G; Hu G
Int J Psychiatry Clin Pract; 2014 Oct; 18(4):229-42. PubMed ID: 25152019
[TBL] [Abstract][Full Text] [Related]
5. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.
Gunes A; Melkersson KI; Scordo MG; Dahl ML
J Clin Psychopharmacol; 2009 Feb; 29(1):65-8. PubMed ID: 19142110
[TBL] [Abstract][Full Text] [Related]
6. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients.
Bozina N; Kuzman MR; Medved V; Jovanovic N; Sertic J; Hotujac L
J Psychiatr Res; 2008 Jan; 42(2):89-97. PubMed ID: 17113599
[TBL] [Abstract][Full Text] [Related]
7. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M
J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475
[TBL] [Abstract][Full Text] [Related]
8. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.
Ujike H; Nomura A; Morita Y; Morio A; Okahisa Y; Kotaka T; Kodama M; Ishihara T; Kuroda S
J Clin Psychiatry; 2008 Sep; 69(9):1416-22. PubMed ID: 19193342
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Houston JP; Kohler J; Bishop JR; Ellingrod VL; Ostbye KM; Zhao F; Conley RR; Poole Hoffmann V; Fijal BA
J Clin Psychiatry; 2012 Aug; 73(8):1077-86. PubMed ID: 22967772
[TBL] [Abstract][Full Text] [Related]
10. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
[TBL] [Abstract][Full Text] [Related]
11. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
Perez-Iglesias R; Mata I; Pelayo-Teran JM; Amado JA; Garcia-Unzueta MT; Berja A; Martinez-Garcia O; Vazquez-Barquero JL; Crespo-Facorro B
Schizophr Res; 2009 Feb; 107(2-3):115-21. PubMed ID: 18993033
[TBL] [Abstract][Full Text] [Related]
12. Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up.
Medved V; Kuzman MR; Jovanovic N; Grubisin J; Kuzman T
J Psychopharmacol; 2009 Nov; 23(8):915-22. PubMed ID: 18635691
[TBL] [Abstract][Full Text] [Related]
13. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.
Hardy TA; Marquez E; Kryzhanovskaya L; Taylor CC; Cavazzoni P
J Clin Psychopharmacol; 2006 Aug; 26(4):405-8. PubMed ID: 16855460
[TBL] [Abstract][Full Text] [Related]
14. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia.
Mulder H; Franke B; van der-Beek van der AA; Arends J; Wilmink FW; Scheffer H; Egberts AC
J Clin Psychopharmacol; 2007 Aug; 27(4):338-43. PubMed ID: 17632216
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis.
Templeman LA; Reynolds GP; Arranz B; San L
Pharmacogenet Genomics; 2005 Apr; 15(4):195-200. PubMed ID: 15864111
[TBL] [Abstract][Full Text] [Related]
16. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Saddichha S; Ameen S; Akhtar S
J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
[TBL] [Abstract][Full Text] [Related]
17. Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients.
Yasui-Furukori N; Tsuchimine S; Saito M; Nakagami T; Sato Y; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1230-4. PubMed ID: 17559997
[TBL] [Abstract][Full Text] [Related]
18. -759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment.
Ryu S; Cho EY; Park T; Oh S; Jang WS; Kim SK; Lee D; Hong KS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):673-7. PubMed ID: 17275977
[TBL] [Abstract][Full Text] [Related]
19. The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia.
Lin YC; Ellingrod VL; Bishop JR; Miller DD
Ther Drug Monit; 2006 Oct; 28(5):668-72. PubMed ID: 17038883
[TBL] [Abstract][Full Text] [Related]
20. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
